National Pension Service increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 1.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 539,530 shares of the pharmaceutical company’s stock after buying an additional 7,461 shares during the quarter. National Pension Service owned about 0.21% of Vertex Pharmaceuticals worth $268,001,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in VRTX. Summit Global Investments purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth approximately $3,568,000. Allworth Financial LP raised its position in Vertex Pharmaceuticals by 414.1% in the fourth quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock valued at $6,363,000 after purchasing an additional 11,306 shares during the period. Calamos Advisors LLC raised its position in Vertex Pharmaceuticals by 77.1% in the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock valued at $34,779,000 after purchasing an additional 33,917 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its stake in Vertex Pharmaceuticals by 11.9% during the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock worth $15,625,000 after purchasing an additional 3,710 shares in the last quarter. Finally, Meiji Yasuda America Inc acquired a new position in Vertex Pharmaceuticals during the fourth quarter worth $1,911,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Vertex Pharmaceuticals
In related news, CMO Carmen Bozic sold 596 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $482.50, for a total value of $287,570.00. Following the completion of the transaction, the chief marketing officer owned 15,337 shares in the company, valued at $7,400,102.50. The trade was a 3.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan McKechnie sold 1,541 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares in the company, valued at approximately $5,709,519. This represents a 12.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,719 shares of company stock valued at $4,174,147 over the last 90 days. 0.20% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on VRTX
Vertex Pharmaceuticals Stock Down 1.5%
NASDAQ:VRTX opened at $521.12 on Thursday. Vertex Pharmaceuticals Incorporated has a 52 week low of $374.17 and a 52 week high of $560.25. The company has a fifty day simple moving average of $511.53 and a two-hundred day simple moving average of $472.59. The company has a market cap of $132.26 billion, a price-to-earnings ratio of 30.33, a price-to-earnings-growth ratio of 2.29 and a beta of 0.32.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The company had revenue of $3.33 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter last year, the business posted $4.52 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 16.88 EPS for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.
Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
